Skip to content
POM-V Prescription Required

Equip F

Active ingredient: Equine influenza virus

Form

Injection

Species

Horses

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5231

What it's used for

Onset of immunity: within 2 weeks of completion of the primary course Duration of immunity: 15 months.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Equine influenza virus

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Equip F — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity: within 2 weeks of completion of the primary course
Duration of immunity: 15 months.
Administration: Equip F should be shaken thoroughly before use, and administered
by deep intramuscular injection.
Vaccination schedule: For protection against quine influenza, Equip F should be
used as follows:
Primary Course First dose EQUIP F
6 week interval
Second dose EQUIP F
5 month interval
Boosters 1
st
booster EQUIP F
12-15 month interval
nd
and subsequent boosters EQUIP F
12-15 month intervals
Note: The routine practice of administering booster doses annually may remain the
most convenient, even though protection against equine influenza has been
demonstrated by challenge studies 15 months following the third vaccination (first
booster dose). No field challenge studies have been carried out prior to the third
vaccination; instead efficacy was evaluated by serology which showed titres
equivalent to those found in horses protected against challenge at 15 months.
It is recommended that a single booster dose should only be administered to horses
that have already received a full primary course using vaccines that contain the
same types of equine influenza virus included in this vaccine. A full primary course
may be considered necessary in horses that have not been suitably primed.
None.
Horses.
Rare
(1 to 10 animals / 10,000
animals treated):
Injection site swelling
1,3
Stiffness
Elevated temperature
1, 2
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Injection site pain
Hypersensitivity reaction
Anorexia, Lethargy
This condition normally resolves by the day following vaccination.
Mild, transient, typically 9-12 hours post vaccination.
Local, small (10-20 mm in diameter), soft, non-painful.
In the event of an allergic or anaphylactic reaction, immediate treatment should be
given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or the national competent authority via
the national reporting system. See the package leaflet for respective contact details.
Vaccinate healthy animals only.

Special precautions for safe use in the target species:
The efficacy of active immunisation of young foals against equine influenza will be
influenced by the level of maternally derived antibodies. This will vary between
individuals due to a number of factors, e.g. the immune status of the dam; adequacy
of colostral intake by the foal etc. The vaccine should not be used in foals below 5
months of age, and foals should not be vaccinated until maternally derived
antibodies have fallen below protective levels.
In any animal population there may be a small number of individuals which fail to
respond fully to vaccination. Successful vaccination depends upon correct storage
and administration of the vaccine and the ability of the animal to respond. This can
be influenced by such factors as genetic constitution, intercurrent infection, age,
nutritional status, concurrent drug therapy and stress.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
The product should be administered by respecting appropriate (aseptic) injection
technique
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.
Store in a refrigerator (2 °C - 8 °C).
Protect from light.
Do not freeze.
Keep the container in the outer carton.
Zero days.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.